Velocity Clinical Research, Inc.

We’re proud to share that Nick Spittal, Chief Operations Officer at Velocity, played a key role in shaping a new industry-wide initiative to streamline Confidential Disclosure Agreements (CDAs)—a critical step in speeding up clinical trial startup. As one of 21 contributing authors from leading sponsors, CROs, and research sites, Nick helped develop a mutual master CDA template and best practices endorsed by the Site-Sponsor Consortium. This effort addresses a long-standing bottleneck in clinical research and offers practical solutions to reduce delays and improve collaboration across the industry. Why it matters: - CDAs are often the first hurdle in trial feasibility. - Delays in CDA execution can push study startup back by weeks or months. - The new template and processes promote efficiency, mutual protection, and faster site activation. Velocity is committed to driving innovation in clinical operations—and this initiative is a powerful example of what’s possible when the industry comes together to solve shared challenges. Learn more about the CDA streamlining initiative and download the template at the link below. #ClinicalResearch #StudyStartup #CDAstreamlining #SiteSponsorConsortium #InnovationInTrials #ResearchEfficiency

Last week, our Waco team hosted the 2025 MASH BASH Liver & Metabolic Education Series in Waco, TX! Over 120 community clinicians, and their guests, gathered to connect and engage the topics of liver disease and obesity. We heard presentations from Jonatan Garcia, MPH on the Work of Velocity Waco and Nadege Gunn, MD, CPI, DABOM, FAASLD on MASH Updates, including the latest diagnostic and treatment options for MASH (metabolic dysfunction-associated steatohepatitis). The evening ended with our Signature Innovations Symposium, presented by Boehringer Ingelheim, titled "How Can We Better Understand Obesity?" by Dr. Joel Solis of Elevate Clinical Research. Special thanks to our sponsors: - Signature Innovations Symposium Sponsor: Boehringer Ingelheim - Presenting Sponsors: Gilead Sciences & Perspectum Ltd - Silver Sponsors: Madrigal Pharmaceuticals, Echosens, 89bio, Akero Therapeutics, Novo Nordisk - Supporting Sponsors: Corcept Therapeutics & ModifyHealth

This month’s Recap kicks off with an excerpt from a new article by Paul Evans on Velocity’s strategy as it grows toward $500M in revenue. Also in this edition:  • Connect with our team at #SCRS2025 • Highlights from the 2025 Velocity Patient Survey • Browse the new Velocity case study library #VelocityAtScale #ClinicalResearch #ClinicalTrials

Heading to Orlando? Let’s talk about your upcoming trials at #SCRS2025. Stop by booth 219 or connect with our team now to schedule a meeting!  • Paul Evans • Sara Smiley, DO, FACP • Craig Koch • Jennifer Carl • Dan Robitaille • Paul Kergides • Grant Miller • Jillian Cueto • Chandler Starr • Jordan Grahm Tower #SCRS

Velocity established on-site laboratory capabilities at a few sites to support specific client needs. What started as a specialized capability formalized into an integrated, global network of laboratory solutions. Today, Velocity can provide 100% in-network lab services, including peripheral blood mononuclear cell (PBMC) collection, processing, and analysis for 30+ locations across the U.S. and Europe.  Equipped with cutting-edge technology and expert staff, our labs offer advanced sample processing and best-in-class equipment. It’s another way Velocity delivers unmatched speed, efficiency, and data accuracy for trials worldwide. https://lnkd.in/gjPkG372 

In the past five years, Velocity has supported trials that have led to more than a dozen FDA vaccine approvals. Velocity’s Vaccine CARE Council ensures all Velocity sites meet best practices established by top vaccine researchers. Their guidance helps ensure each Velocity site can deliver:   • Rapid enrollment for high-volume studies   • Access to hard-to-reach specialty populations  • Consistent quality across a global footprint Learn more about Velocity’s vaccine research capabilities: https://lnkd.in/gjvE8ERi #ClinicalTrials #Vaccines #VelocityAtScale #PatientRecruitment #ClinicalResearch 

The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s site in Dallas, TX, point to a potential solution. The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean mass loss typically associated with GLP-1 therapy, while increasing fat loss. As the lead investigator for the trial, Dr. Rosenstock stated in the Regeneron press release: "These complete 26-week COURAGE results demonstrate a meaningful opportunity to preserve muscle mass while enhancing fat loss." Also noted: "Numerical improvements in metabolic and lipid parameters, secondary and exploratory endpoints, were seen across all treatment groups, including improvements in waist circumference, blood pressure, cholesterol, triglycerides and A1C." Read the full press release: https://lnkd.in/gAYTYqgm #ClinicalResearch #Obesity #GLP1 #semaglutide 

Before your trial starts, Velocity can accelerate your site selection processes by providing fast, accurate feasibility responses and a ‘one contact, one contract’ approach for all sites. Working at scale, Velocity has also driven 50% faster IRB review cycles compared to peers (includes submission, clarification, and approval timelines). Learn more about Velocity at Scale: https://lnkd.in/g7En6sbT #VelocityAtScale #ClinicalTrials

Velocity has delivered thousands of participants for several trials over the past year. At scale, Velocity can deliver more participants per site, faster. See how our integrated model consistently outperforms industry averages: https://lnkd.in/gk9-SgQg #ClinicalTrials #VelocityAtScale #ClinicalResearch 

Heading to #SCRS2025? Connect with our team at booth 219 in Orlando! At this event:  • Paul Evans  • Sara Smiley, DO, FACP  • Craig Koch • Jennifer Carl • Dan Robitaille • Paul Kergides • Grant Miller • Jillian Cueto